Interleukin-3 Receptor alpha Subunit
"Interleukin-3 Receptor alpha Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low affinity interleukin-3 receptor subunit that combines with the CYTOKINE RECEPTOR COMMON BETA SUBUNIT to form a high affinity receptor for INTERLEUKIN-3.
| Descriptor ID |
D053650
|
| MeSH Number(s) |
D12.776.543.750.705.852.420.340.500
|
| Concept/Terms |
Interleukin-3 Receptor alpha Subunit- Interleukin-3 Receptor alpha Subunit
- Interleukin 3 Receptor alpha Subunit
- Interleukin-3 Receptor alpha Chain
- Interleukin 3 Receptor alpha Chain
- Antigens, CD123
- CD123 Antigens
- alpha-Subunit, Receptor, Interleukin-3
- CD123 Antigen
- Antigen, CD123
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-3 Receptor alpha Subunit".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-3 Receptor alpha Subunit".
This graph shows the total number of publications written about "Interleukin-3 Receptor alpha Subunit" by people in this website by year, and whether "Interleukin-3 Receptor alpha Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 4 | 4 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-3 Receptor alpha Subunit" by people in Profiles.
-
Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile. Blood Adv. 2024 05 14; 8(9):2059-2073.
-
Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. Cancer. 2024 Jul 01; 130(13):2260-2271.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations. Leuk Lymphoma. 2024 May; 65(5):548-559.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Peptide-scFv antigen recognition domains effectively confer CAR T?cell multiantigen specificity. Cell Rep Med. 2024 Feb 20; 5(2):101422.
-
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e130-e137.
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
-
Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023 May; 21(5):257-264.